The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Children born with HIV accessing treatment, have no significant difference in their movement skills, social interaction, language skills or practical reasoning at age five compared to HIV-negative children, according to new research. However, some visual impairments were detected in the groups.
The study followed around 200 newborns aged 12-weeks-and-under from Cape Town, South Africa, between 2006 and 2013. Of the infants included in the study, 119 were HIV-positive, while 84 were HIV negative.
Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness.
New study provides insights into the factors that influence treatment adherence in Latin America and the Caribbean. Results show that individuals from lower resource settings often achieve higher levels of adherence, contrary to predictions.
Lancet study reveals for the first time who can benefit most from immediate antiretroviral treatment – enabling prioritisation in low-resourced settings. But who is left behind?
Immediate antiretroviral treatment (ART) for people with low CD4 counts in China reduces overall mortality by 63% – confirming trials in other countries that have shown the benefit of early treatment for improved health outcomes.
Agreement ushers in first single-dose, affordable HIV treatment for low- and middle-income countries.
A pilot that saw health workers adopt ‘patient-centred’ communication at an HIV clinic in rural Tanzania led to a three-fold increase in the number of people openly reporting treatment adherence problems.
UNITAID partners to bring newer and more effective HIV treatment options to countries where they are needed most.
Key HIV drugs added to the list of medicines critical to public health, including tenofovir for HIV prevention, and dolutegravir.
The country with the third largest HIV epidemic moves to a test-and-treat strategy that aims to get everyone on antiretroviral therapy.
The first trials enhancing orally-taken antiretroviral treatment with Solid Drug Nanoparticle technology have produced “incredibly promising” results.